Chemistry:Potassium channel opener
From HandWiki
Short description: Type of drug
A potassium channel opener is a type of drug which facilitates ion transmission through potassium channels.
Examples
Some examples include:
- Diazoxide[1] vasodilator used for hypertension, smooth muscle relaxing activity
- Minoxidil[2] vasodilator used for hypertension, also used to treat hair loss
- Nicorandil[3] vasodilator used to treat angina
- Pinacidil[4]
- Retigabine,[5][6] an anticonvulsant
- Flupirtine, analgesic with muscle relaxant and anticonvulsant properties
| Class | Subclasses | Activators |
|---|---|---|
| Calcium-activated
6T & 1P |
| |
| Inwardly rectifying
2T & 1P |
| |
| ||
| ||
| Tandem pore domain
4T & 2P |
||
| Voltage-gated
6T & 1P |
|
See also
References
- ↑ "Myocyte volume and function in response to osmotic stress: observations in the presence of an adenosine triphosphate-sensitive potassium channel opener". Circulation 112 (9 Suppl): I219–23. August 2005. doi:10.1161/CIRCULATIONAHA.104.523746. PMID 16159820.
- ↑ Wang T (February 2003). "The effects of the potassium channel opener minoxidil on renal electrolytes transport in the loop of henle". J. Pharmacol. Exp. Ther. 304 (2): 833–40. doi:10.1124/jpet.102.043380. PMID 12538840.
- ↑ "Nicorandil, a potassium channel opener and nitric oxide donor, improves the frequent urination without changing the blood pressure in rats with partial bladder outlet obstruction". Biol. Pharm. Bull. 31 (11): 2079–82. November 2008. doi:10.1248/bpb.31.2079. PMID 18981577.
- ↑ "Potassium channel opener pinacidil induces relaxation of the isolated human radial artery". J. Pharmacol. Sci. 104 (2): 122–9. June 2007. doi:10.1254/jphs.FP0061434. PMID 17538231. [|permanent dead link|dead link}}]
- ↑ Rundfeldt C (October 1997). "The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells". European Journal of Pharmacology 336 (2–3): 243–9. doi:10.1016/S0014-2999(97)01249-1. PMID 9384239.
- ↑ "Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine". Molecular Pharmacology 58 (2): 253–62. August 2000. doi:10.1124/mol.58.2.253. PMID 10908292.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 "Molecular background of leak K+ currents: two-pore domain potassium channels". Physiological Reviews 90 (2): 559–605. Apr 2010. doi:10.1152/physrev.00029.2009. PMID 20393194. http://repo.lib.semmelweis.hu//bitstream/123456789/8205/1/2010PhysiolRev_K2P.pdf.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 "Biophysical, pharmacological, and functional characteristics of cloned and native mammalian two-pore domain K+ channels". Cell Biochemistry and Biophysics 47 (2): 209–56. 2007. doi:10.1007/s12013-007-0007-8. PMID 17652773.
- ↑ 9.0 9.1 "A neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids". The EMBO Journal 17 (12): 3297–308. Jun 1998. doi:10.1093/emboj/17.12.3297. PMID 9628867.
- ↑ "Potassium leak channels and the KCNK family of two-P-domain subunits". Nature Reviews. Neuroscience 2 (3): 175–84. Mar 2001. doi:10.1038/35058574. PMID 11256078. https://escholarship.org/uc/item/9z7112ns.
- ↑ "A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord". The Journal of Biological Chemistry 278 (30): 27406–12. Jul 2003. doi:10.1074/jbc.M206810200. PMID 12754259.
- ↑ "The two-pore domain K+ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin". The Journal of Biological Chemistry 279 (18): 18550–8. Apr 2004. doi:10.1074/jbc.M312229200. PMID 14981085.
- ↑ "Functional characterisation of human TASK-3, an acid-sensitive two-pore domain potassium channel". Neuropharmacology 40 (4): 551–9. Mar 2001. doi:10.1016/S0028-3908(00)00189-1. PMID 11249964.
- ↑ "Inhalational anesthetics activate two-pore-domain background K+ channels". Nature Neuroscience 2 (5): 422–6. May 1999. doi:10.1038/8084. PMID 10321245.
- ↑ "Volatile anesthetics activate the human tandem pore domain baseline K+ channel KCNK5". Anesthesiology 92 (6): 1722–30. Jun 2000. doi:10.1097/00000542-200006000-00032. PMID 10839924.
- ↑ "New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels". Current Neurology and Neuroscience Reports 8 (4): 345–52. Jul 2008. doi:10.1007/s11910-008-0053-7. PMID 18590620.
- ↑ "TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101". Annals of Clinical and Translational Neurology 6 (11): 2164–2174. November 2019. doi:10.1002/acn3.50896. PMID 31568714. "XEN1101 is a novel positive allosteric modulator (“opener”) of the potassium channel KCNQ2/3 (Kv7.2/7.3) currently being developed by Xenon Pharmaceuticals Inc. for the treatment of focal epilepsy.".
 |  |
